NASDAQ · SXTP
60 Degrees Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SXTP: Nov 12, 2026
60 Degrees Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.73. The reported EPS for the same quarter last year was $-2.64.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.73 | $-0.61 | $-0.85 | 2 |
| Dec 2026 | $-0.78 | $-0.67 | $-0.89 | 2 |
| Mar 2027 | $-0.90 | $-0.90 | $-0.90 | 1 |
| Jun 2027 | $-0.88 | $-0.88 | $-0.88 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Oct 28, 11:29 AM EDT60 Degrees Pharma Expands Research Into Alpha-Gal Syndrome; Stock Up(RTTNews) – 60 Degrees Pharmaceuticals, Inc. (SXTP) a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced a sponsored research agreement with The University of Southern Mississippi (USM) to evaluate the therapeutic potential of castanos
- Fintel · Oct 27, 11:20 AM EDT60 Degrees Pharmaceuticals, Inc. Reports Results from Expanded Access Babesiosis Study60 Degrees Pharmaceuticals, Inc. announced clinical and molecular results from the first five patients to complete treatment with tafenoquine-containing combination regimens in the Company’s expanded access study of relapsing babesiosis in immunosuppressed patients. All fiv
- RTTNews · Oct 27, 10:28 AM EDT60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down(RTTNews) – 60 Degrees Pharmaceuticals (SXTP) reported clinical improvement and negative conventional PCR results for all five patients who completed treatment in its expanded access study of tafenoquine-containing regimens for relapsing babesiosis. Four of the five patients also
- Fintel · Oct 23, 9:02 AM EDT60 Degrees Pharmaceuticals, Inc. Outlines Tafenoquine Clinical Program for Babesiosis and Potential sNDA in 202760 Degrees Pharmaceuticals, Inc. updated its investor presentation on October 23, 2026, outlining the clinical development of tafenoquine for human babesiosis. The company is planning for a potential sNDA in 2027 and has submitted a statement of interest requesting a national-pri
- RTTNews · Oct 6, 9:37 AM EDT60 Degrees To Unblind Babesiosis Study In January 2027; Plans FDA Meeting Following Interim Review(RTTNews) – 60 Degrees Pharmaceuticals (SXTP) said it plans to unblind its study of tafenoquine in hospitalised patients with severe babesiosis in January 2027 and will request a pre-supplemental New Drug Application (sNDA) meeting with the FDA that same month following a schedul
- RTTNews · Oct 6, 3:54 AM EDTBabesiosis Data Readout Today As 60 Degrees Pharmaceuticals Shares Climb(RTTNews) – Shares of 60 Degrees Pharmaceuticals, Inc. (SXTP) were up about 18% as investors awaited the company's interim data release today from its Phase 2 study evaluating tafenoquine in patients hospitalized with severe babesiosis.
- RTTNews · Aug 17, 5:23 AM EDT60 Degrees Pharma Q2 Net Loss Widens Despite 106% Product Revenue Growth; Stock Up(RTTNews) – 60 Degrees Pharmaceuticals, Inc. (SXTP) reported financial results for the second quarter of 2026, reflecting a wider net loss despite 106% growth in product revenue, as higher operating expenses more than offset the increase in revenue.
- Zacks · Aug 10, 8:05 PM EDTHarrow (HROW) Reports Q2 Loss, Misses Revenue EstimatesHarrow (HROW) delivered earnings and revenue surprises of -47.83% and -0.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 7:10 AM EDTMerck KGaA (MKKGY) Misses Q2 Earnings EstimatesMerck KGaA (MKKGY) delivered earnings and revenue surprises of -44.68% and +3.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 31, 11:00 AM EDT60 Degrees Pharmaceuticals Prices $1.0M Private Placement At $1.74 Per Share; Stock Down(RTTNews) – 60 Degrees Pharmaceuticals, Inc. (SXTP), a company focused on developing medicines for vector-borne diseases, announced Thursday that it has entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules.
- RTTNews · Jul 9, 4:14 AM EDT60 Degrees Pharma Signs FSU Deal To Advance Castanospermine For Tick-Borne Diseases(RTTNews) – 60 Degrees Pharmaceuticals, Inc. (SXTP), which develops treatment for vector-borne disease, announced that it has entered into an exclusive option agreement with the Florida State University Research Foundation (FSURF) covering intellectual property related to the dev
- RTTNews · Jul 2, 3:49 AM EDT60 Degrees' Phase 2 B-Free Babesiosis Study Of ARAKODA Clears Safety Board Review(RTTNews) – 60 Degrees Pharmaceuticals, Inc. (SXTP), a pharmaceutical company, on Wednesday announced that an independent Data Safety Monitoring Board has recommended continuing its Phase 2 B-Free chronic Babesiosis study after reviewing safety data from the first six patients th
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for 60 Degrees Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.